Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial

BACKGROUND: Etrolizumab is a gut-targeted anti-β7 monoclonal antibody targeting α4β7 and αEβ7 integrins. We aimed to compare the safety and efficacy of two doses of etrolizumab with placebo in patients with Crohn's disease. METHODS: BERGAMOT was a randomised, placebo-controlled, double-blind, p...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	LANCET GASTROENTEROLOGY & HEPATOLOGY 2023-01, Vol.8 (1), p.43-55
Hauptverfasser:	Sandborn, William J, Panes, Julian, Danese, Silvio, Sharafali, Zaineb, Hassanali, Azra, Jacob-Moffatt, Rhian, Eden, Christopher, Daperno, Marco, Valentine, John F, Laharie, David, Baia, Carolina, Atreya, Raja, Panaccione, Remo, Rydzewska, Grazyna, Aguilar, Humberto, Vermeire, Severine
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!